Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience.
Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience.
复制标题
DOI：
10.1046/j.1524-4741.2001.07604.x
复制
发表时间：
2001-11-01
期刊：
影响因子：
--
通讯作者：
Rahbar, M H
中科院分区：
文献类型：
--
作者：
Aziz, S A;Pervez, S;Rahbar, M H
炎性乳腺癌 (IBC) 是一种罕见但具有侵袭性的乳腺癌。在这项首次研究中，我们研究了与对照组相比，IBC 病例中九种预后标志物的表达（雌激素受体 [ER]、孕激素受体 [PR]、p53、C-erbB-2、表皮生长因子受体 [EGFR]、组织蛋白酶 D [CD]、增殖细胞核抗原 [PCNA]、DNA 倍体和 S 期分数 [SPF]）和疾病结果的作用。对 40 个测试病例进行了 IBC 病例对照研究，每个病例有两个对照，与年龄、分级和采集的腋窝淋巴结数量相匹配。在这项为期 7 年的研究中，所有乳腺癌患者中有 10% 患有 IBC。在这项研究中，84% 的 IBC 病例显示腋窝淋巴结阳性，而对照组为 63%。通过免疫组化和流式细胞术研究了 ER、PR、p53、C-erbB-2、EGFR、CD、PCNA、SPF 和 DNA 倍体 9 种预后标志物的表达。激素受体状态呈负相关（p < 0.05）。在 IBC 组的 p53、C-erbB-2、EGFR 和 CD 中，只有 p53 显示出显着相关性，IBC 组的阳性率为 70%，而对照组的阳性率为 48%（p < 0.05）。与对照组相比，IBC 组的 SPF 和 PCNA 阳性率更高（p < 0.05）。与对照组相比，DNA 倍性也显示出显着相关性（p < 0.05）。中位随访 18 个月后，IBC 组的中位总生存期为 1.8 年（范围 0.6-5.8 年），而中位总生存期为 3.0 年（范围 2.5-7.0 年），p 值为 0.0001。
Inflammatory breast carcinoma (IBC) is a rare but aggressive form of breast cancer. In this first-ever study, we investigated the role of nine prognostic markers' expression (estrogen receptor [ER], progesterone receptor [PR], p53, C-erbB-2, epidermal growth factor receptor [EGFR], cathepsin D [CD], proliferating cell nuclear antigen [PCNA], DNA ploidy, and S-phase fraction [SPF]) and disease outcome in IBC cases compared with the control group. A case control study of IBC was conducted on 40 test cases with two controls per case matching age, grade, and number of axillary lymph nodes sampled. During 7 years of this study, 10% of all patients with breast cancer had IBC. In this study, 84% of IBC cases showed positive axillary lymph nodes compared with 63% in control group. The expression of nine prognostic markers, that is, ER, PR, p53, C-erbB-2, EGFR, CD, PCNA, SPF, and DNA ploidy, was studied by immunohistochemistry and flow cytometry. Hormone receptor status showed an inverse correlation (p < 0.05). Among p53, C-erbB-2, EGFR, and CD in the IBC group, only p53 showed a significant correlation, with 70% positivity in IBC versus 48% positivity in the control group (p < 0.05). Much higher SPF and PCNA positivity was seen in the IBC group compared with the control group (p < 0.05). DNA ploidy also showed a significant correlation compared with the control group (p < 0.05). After a median follow up of 18 months, median overall survival in the IBC group was 1.8 years (range 0.6-5.8 years) compared with 3.0 years (range 2.5-7.0 years), with a p value of 0.0001.